ArticleBMC endocrine disorders2025
Triglyceride-glucose index in diabetic chronic complications in patients with type 2 diabetes mellitus.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore the relationship between the triglyceride-glucose (TyG) index and diabetic chronic complications 922 patients with type 2 diabetes mellitus (T2DM) hospitalized in the Affiliated Suqian Hospital of Xuzhou Medical University from November 2023 to July 2024 and the Second Affiliated Hospital of Soochow University from January 2019 to December 2020 were enrolled. We divided the patients into different complications groups and corresponding non-compication groups. Clinical and biochemical parameters were compared between the two groups.The TyG index was determined by the following formula: Ln [TG(mg/dl)×FBG(mg/dl)/2], where TG is triglycerides and FBG is fasting blood glucose.
results(1) The TyG index showed significant positive correlation with diabetic retinopathy (DR) and carotid plaque (CP), while demonstrating inverse correlations with high density lipoprotein cholesterol (HDL-c) and 25-hydroxyvitamin D [25(OH)D] levels. (2) Among patients with DR, duration, TyG index and the prevalence of diabetic kidney disease (DKD) and diabetic peripheral neuropathy (DPN) were significantly higher. (3) Among patients with CP, age and TyG index were significantly higher. 922 patients with type 2 diabetes mellitus (T2DM) hospitalized in the Affiliated Suqian Hospital of Xuzhou Medical University from November 2023 to July 2024 and the Second Affiliated Hospital of Soochow University from January 2019 to December 2020 were enrolled. We divided the patients into different complications groups and corresponding non-compication groups. Clinical and biochemical parameters were compared between the two groups.The TyG index was determined by the following formula: Ln [TG(mg/dl)×FBG(mg/dl)/2], where TG is triglycerides and FBG is fasting blood glucose. (1) The TyG index showed significant positive correlation with diabetic retinopathy (DR) and carotid plaque (CP), while demonstrating inverse correlations with high density lipoprotein cholesterol (HDL-c) and 25-hydroxyvitamin D [25(OH)D] levels. (2) Among patients with DR, duration, TyG index and the prevalence of diabetic kidney disease (DKD) and diabetic peripheral neuropathy (DPN) were significantly higher. (3) Among patients with CP, age and TyG index were significantly higher.
conclusionHigh TyG index is a relative specific risk factor of diabetic retinopathy and carotid plaque in patients with type 2 diabetes and not a contributing factor to the other chronic complications of diabetes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.